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S€AFHOLM ET AL 985by a second and much larger contraction (maximum effect
[Emax], 47% 6 5%) when mannitol was washed out. The mast
cell stabilizer cromolyn reduced the second contraction
(Emax, 27% 6 3%). Furthermore, this main contraction was
abolished by the combination of antagonists of histamine and
cysteinyl leukotrienes in the presence of indomethacin. Mannitol
increased the release of the mast cell mediators histamine
(9.0-fold), cysteinyl leukotrienes (4.5-fold), and prostaglandin
(PG) D2 (5.4-fold), as well as PGE2 (6.3-fold) and the
prostacyclin metabolite 6-keto PGF1a (5.7-fold). In contrast,
indomethacin alone enhanced the bronchoconstriction
(Emax, 68% 6 6%). Likewise, receptor antagonists for PGE2
(EP2 and EP4) and prostacyclin (IP) also enhanced the
mannitol-induced bronchoconstriction (Emax, 67% 6 5%,
66% 6 4%, and 68% 6 3%, respectively). In bronchi
precontracted by carbachol, the IP receptor agonist cicaprost
induced profound relaxation.
Conclusion: This new protocol established an in vitro model for
studies of EIB in isolated human bronchi. The IP receptor might
be a new target for asthma treatment. (J Allergy Clin Immunol
2019;144:984-92.)
Key words: Hyperosmolar challenge, exercise-induced bronchocon-
striction, prostaglandin D2, prostaglandin E2, prostaglandin I2,
EP2 receptor, EP4 receptor, prostacyclin receptor, histamine,
nonsteroidal anti-inflammatory drugs
Exercise-induced bronchoconstriction (EIB) can occur in elite
athletes without asthma but is most commonly recognized as a
form of airway hyperresponsiveness that is highly overrepre-
sented in asthmatic patients.1,2 EIB is a consequence of the
increased ventilation and water loss during exercise, which in
turn leads to hyperosmolarity of the airway tissues and triggering
of mast cells to release the mediators that cause contraction of the
airway smooth muscle.3 Accordingly, leukotriene (LT) receptor
antagonists and mast cell stabilizers can attenuate EIB, and func-
tional antagonism by short-acting b2-adrenoceptor agonists has
been the conventional strategy to prevent or reverse EIB.4 Thus
far, however, no treatment can completely alleviate the symptoms
or prevent the induction of EIB.
Many mechanisms that regulate airway tone after an exercise
challenge remain unresolved. For example, a protective role for
prostaglandin (PG) E2 has been implicated in patients with EIB
because inhalation of PGE2 can attenuate the reaction,
5 whereas
treatment with nonsteroidal anti-inflammatory drugs blocks the
reduced EIB that normally occurs when the exercise challenge
is repeated within a few hours from the first challenge.6,7 This
nonsteroidal anti-inflammatory drug–sensitive refractoriness in-
dicates that some COX-derived prostanoids are protective, but it
remains to be determined how such protective signaling pathways
are triggered, which particular prostanoids are involved, and how
bronchoconstrictive and bronchoprotective actions interact.
One strategy to investigate EIB in asthmatic patients is through
inhalation of hyperosmolar concentrations of mannitol,8 which
induces bronchoconstriction and release of mast cell mediators
in a similar manner as exercise.9,10 It was recently established
that bronchoconstriction induced by another EIB-mimetic, eu-
capnic voluntary hyperpnea with dry air, as expected, was associ-
ated with increased release of PGE2 from the airways, but in
addition, it was discovered that prostacyclin (PGI2) also was
released during the reactions.11 In the in vivo setting in humansubjects, it is difficult to define the precise mechanisms involved
because there are no available drugs to selectively intervene with
biosynthesis or receptors of specific prostanoids. A general need
for a better understanding of the underlying processes in patients
with EIB was one major incentive for the current study aiming at
development of a new experimental model for translational
research on mechanisms in patients with EIB.
We have previously reported how isolated human small bronchi
can be activated by anti-IgE to produce mast cell–dependent
contractions that are inhibited by PGE2.
12 Therefore it was
considered that mannitol challenge of this particular preparation
might offer an experimental model suitable to investigate the
role of prostanoids and other mediators from the point of view
of mechanisms of EIB.
The strength of using explanted intact bronchi is that the smooth
muscle appears in its natural context close to structural cells and
mast cells. It has been established that isolated human mast cells
indeed release their mediators in response to hyperosmolar
mannitol.13,14 However, the approach involved challenges because
previous investigations using prolonged exposure to hyperosmolar
NaCl in bovine tracheal strips15 or mannitol in human bronchi16
found that the observed contractions were resistant to different
pharmacologic agents, including mast cell inhibitors.
Knowing that mast cell–induced contractions of human
airways develop within minutes after anti-IgE exposure12 and
that cumulative mannitol inhalation in human subjects uses a pro-
tocol in which doses are increased every minute,8 we hypothe-
sized that a short-term exposure of mannitol might uncover the
mast cell activation. Therefore a new ‘‘hit-and-run’’ protocol
was established in which a brief 10-minute exposure of the
bronchi to hyperosmolar mannitol was followed by a washout
period. This procedure produced mannitol activation of mast
cell mediator release and the appearance of an EIB-like contrac-
tion that was amenable to confirming pharmacologic antagonism
resembling interventions with exercise challenge in vivo. In addi-
tion, we provide new pharmacologic implications that prostacy-
clin, as well as PGE2, are possible protective factors involved in
the phenomenon of refractoriness to repeated exercise challenge.METHODS
Isolated tissue preparation
With permission of the Regional Ethical Review Board in Stockholm
(reference no. 2010/181-31/2), macroscopically healthy human lung tissue
was collected after consent from patients undergoing lobectomy for neo-
plasms (92%) or other reasons (hamartoma, granuloma, or follicular
bronchiolitis; n5 48, 22 female and 26 male subjects; median age, 70 years;
age range, 32-82 years; Table I). One to 3 bronchi were dissected out and
further cut into segments from each lung. In all investigations 1 segment
from each bronchus was used as a control for paired comparisons.
FIG 1. A, Force trace of human isolated bronchi with osmolarity increased to 850 mOsm by exposure to
mannitol (M) during the 50-minute observation period. B, In this protocol mannitol (M) was only present
for 10 minutes, followed by a washout (Wo) period that was followed by a second larger contraction.
A supramaximal concentration of histamine (1 mmol/L) was administrated after 45 minutes in both Fig 1,
A and B (H), but only produced a response in Fig 1, B. C, Paired segments with osmolarity increased
mannitol to either 450, 600, or 850 mOsm by using the protocol from Fig 1, B. Black dots/bars represent
contraction after mannitol (10-minute exposure), andwhite dots/bars represent the maximal contraction af-
ter mannitol washout. Data represent means 6 SEMs (number of patients 5 4-5, number of segments
used 5 5-15).
TABLE I. Patients’ characteristics and tissue responses
Female subjects (n 5 22) Male subjects (n 5 26) P value
Age (y) 67 (57-79) 71 (32-82) .43
Body mass index (kg/m2) 25.6 (17.8-31.9) 26.2 (21.2-39.1) .33
C-reactive protein (mg/L) 3 (1-75) 5 (1-109) .58
Hemoglobin (g/L) 130 (110-145) 140 (104-163) .01
Leukocyte particle concentration (3 109/L) 7 (4.9-15.7) 6.7 (4.1-18.7) .84
Current smoker (no.) 7 11 .56
Ex-smoker (no.) 10 13 .78
COPD (no.) 1 4 .36
Asthma (no.) 2 4 .67
Allergy (no.) 6 7 .99
Emax mannitol (10 min [% of maximum]) 13.75 (0-27.4) 11.25 (0-24.3) .78
Emax after mannitol washout (% of maximum) 45.3 (30.2-71.9) 37.3 (30.9-77.2) .58
Statistical analysis was performed by using the Mann-Whitney U test. Numbers represent absolute values or medians and ranges. An ex-smoker is defined as a person who has not
smoked for the last 12 months.
COPD, Chronic obstructive pulmonary disease.
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solution supplemented with 2.5 mmol/L calcium chloride and 2.1 g/L sodium
bicarbonate. Within 1 hour of the resection, microscopy-aided dissection
isolated bronchial rings with an inner diameter of between 0.5 and 2 mm. The
bronchial ring segments were placed in separate culture plate wells containing
Dulbecco modified Eagle medium (Gibco, Auckland, New Zealand) supple-
mented with 1% penicillin (100 IU/mL; Sigma-Aldrich, St Louis, Mo) and
streptomycin (100 mg/mL; Gibco) under sterile conditions in a humidified
incubator (378C at 95% O2 and 5% CO2), allowing the tissue to equilibrate
overnight.12Experimental set-up
On the experimental day, the rings were mounted horizontally between 2
metal prongs for recording of isometric tension (ADInstruments, Hastings,
UnitedKingdom) by usingmyographs (OrganBathModel 700MO;DMTA/S,
Aarhus, Denmark) containing Krebs-Henseleit buffer solution and kept at
378C and constantly bubbled with carbogen (5% CO2 in O2) to maintain pH at
7.4. Preparations were allowed to equilibrate for 30 minutes with buffer solu-
tion changed every 15minutes, followed by a stepwise increase in tension over
60 minutes to a resting tension of 1.5 mN. KCl (60 mmol/L) was added twice
with a washout in between to ascertain bronchial reactivity and viability. This
FIG 2. Contractions of human small bronchi in response to 10 minutes of increased osmolarity by
mannitol. A, Time-response contraction over 40 minutes (number of patients 5 5-15, number of segments
used 5 5-23). B, Emax displays contraction in relation to maximal contractility in the presence or absence of
mepyramine (1 mmol/L), montelukast (1 mmol/L), SQ-29,548 (1 mmol/L), cromolyn (100 mmol/L), or a triple
combination of mepyramine (1 mmol/L), montelukast (1 mmol/L), and SQ-29,548 (1 mmol/L). Data represent
means6 SEMs (number of patients5 5, number of segments used5 5). C, Time-response contraction over
40 minutes in the presence or absence of indomethacin (3 mmol/L; number of patients 5 8, number of
segments used 5 16). D, Emax displays contraction in relation to maximal contractility in the presence or
absence of indomethacin (3 mmol/L). Data represent means 6 SEMs. *P < .05 and **P < .01.
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allow the segment to return to baseline tension.Assay development
Mannitol was dissolved in the buffer solution to the desired osmolarity
(400, 650, and 850 mOsm) and exchanged with normosmolar (317 mOsm)
buffer solution to study the response of increased osmolarity in the human
airways. In the first experiments mannitol was administered during a 50-
minute time period. For the main experiments, segments were exposed to 850
mOsm mannitol for 10 minutes, which thereafter was exchanged with buffer
for observation of the smooth muscle response over an additional 40 minutes.
Receptor antagonists targeting TP (SQ-29,548), H1 (mepyramine), and cys-
teinyl leukotriene (CysLT) type 1 (montelukast) or the mast cell–stabilizing
agent cromolyn were added 45 minutes before changes in osmolarity to inves-
tigate the receptors involved in the mannitol-induced mast cell response.
Prostanoid contributions were investigated by means of administration of a
nonselective COX enzyme inhibitor (indomethacin); receptor antagonists
targeting EP2 (PF-04418948), EP3 (ONO-AE3-208), and prostacyclin recep-
tor (IP; CAY 10441); and a receptor agonist targeting EP2 (ONO-AE1-259)
45 minutes before changes in osmolarity. During the experiments, drug inter-
ventions were present during both the hyperosmolar and subsequent normos-
molar period. All experiments were ended by addition of histamine (1 mmol/
L) as a reference for the maximal contraction.
Bronchial relaxation was studied in segments exposed to receptor agonists
targeting M3 (carbachol; 1 mmol/L) to produce a stable precontraction before a
cumulative addition of agonists targeting IP (cicaprost) orb2-adrenoceptor (sal-
butamol). These experiments were ended with a combination of the
phosphodiesterase inhibitor (papaverin; 0.1 mmol/L) and the nitric oxide donor
(sodium nitroprusside; 0.1 mmol/L) as a reference for maximal relaxation.Separate segments were denuded from the epithelium by means of luminal
brushingwith a cotton swab to investigate epithelial involvement. The isolated
bronchial rings were collected directly after the experiment and immersed in
plain 4% buffered formaldehyde for at least 24 hours, embedded in paraffin,
and stained with hematoxylin and eosin solution (catalog nos. GHS316 and
E4382) to investigate involvement of the epithelium. This was followed by
sectioning and examination with a light microscope.
Media collection and measurement of released
mediators
The buffer solution surrounding the preparations was collected 20 minutes
after exposure to 850 mOsm mannitol, snap-frozen in liquid nitrogen, and
stored in 2808C until analysis. Histamine levels were measured with glass
fiber–coated microtiter plates (RefLab ApS, Copenhagen, Denmark) and
prepared according to the manufacturer’s instructions. CysLTs, PGD2, PGE2,
and 6-keto PGF1a levels were measured by using an ELISA express kit
(Cayman Chemical, Ann Arbor, Mich), according to the manufacturer’s in-
structions. Detection limits were 20 pg/mL (CysLT), 3.1 pg/mL (PGD2
MOX), 15 pg/mL (PGE2) and 6 pg/mL (6-keto PGF1a), and data were normal-
ized to tissue wet weight.Drugs and suppliers
NaHCO3 CaCl2 and KCl were obtained from VWR (West Chester, Pa).
Histamine dihydrochloride, mepyraminemaleate, mannitol (D-mannitol), sal-
butamol, papaverine, sodium nitroprusside, Krebs-Henseleit buffer, hematox-
ylin and eosin solution, and indomethacin were purchased from Sigma-
Aldrich. ONO-AE3-208 and ONO-AE1-259 were kind gifts from ONO Phar-
maceuticals (Osaka, Japan). Montelukast and cicaprost were obtained from
FIG 3. A and B, Photomicrographs of isolated human bronchial preparations with hematoxylin and eosin
staining depicting intact (Fig 3, A) and denuded (Fig 3, B) bronchial epithelium. Scale bars 5 1 mm. C, Con-
tractions of human small bronchi in response to 10 minutes of increased osmolarity by mannitol. Emax dis-
plays contraction in relation to maximal contractility in the presence or absence of indomethacin (Indo) in
bronchial segments with (1) or without (2) intact epithelium.wo, Washout. Data represent means 6 SEMs
(number of patients 5 5, number of segments used 5 5). *P < .05 and **P < .01. ns, Not significant.
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Division (Groton, Conn). Dulbecco modified Eagle medium were obtained
from Gibco.
Calculations and statistics
Statistical analysis was performed by using paired 1-way ANOVA,
followed by the Bonferroni multiple comparison test, with P values of less
than .05 considered significant. For nonparametric data of patient groups,
the Mann-Whitney U test was used. For analysis, GraphPad Prism 6.01
(GraphPad Software, San Diego, Calif) was used.
RESULTS
Sustained exposure to hyperosmolar mannitol
causes smooth muscle paralysis
Segments were exposed to 850mOsmmannitol, which induced
a small sustained contraction (Emax, 12.1% 6 1.6%; Fig 1, A).
This contraction, which ensued after 1 hour of maintained expo-
sure to hyperosmolarity, was not inhibited by antagonists and in-
hibitors that blocked the effect of histamine, CysLTs, and COX
products (1 mmol/L mepyramine, 1 mmol/L MK-886, and
3 mmol/L indomethacin; n 5 5; data not shown). Moreover, the
preparations were seemingly paralyzed and did not respond to
addition of histamine (Fig 1, A).Brief exposure to hyperosmolar mannitol causes
mast cell–mediated contraction
In contrast, when bronchi were exposed only briefly to
mannitol for 10 minutes, a strong contraction developed as soon
asmannitol was washed away (Fig 1,B). This response reached its
maximum 7 6 1 minutes after the washout period (ie,
17 6 1 minutes from the initial mannitol addition; Fig 1, B).
With this protocol, the preparation displayed normal responsive-
ness to a supramaximal concentration of histamine (Fig 1, B). Re-
sponses to mannitol were also observed for lower concentrations
(450 and 600 mOsm), but 850 mOsm consistently produced the
greatest response and was therefore used for the remainder of
the study (Fig 1, C).
This substantial contraction to the highest dose of mannitol
(Emax, 46.9% 6 4.6%) was attenuated by antagonizing the
CysLT1 receptor with montelukast (Emax, 28.6% 6 4.5%;
P < .05; Fig 2, B). The response to mannitol was numerically
smaller in the presence of either the H1 receptor antagonist me-
pyramine (Emax, 39.0%6 10.2%) or the thromboxane TP recep-
tor SQ-29,548 (Emax, 36.1% 6 1.7%), but neither of these 2
interventions reached significance (P 5 .64 and .75, respec-
tively; Fig 2, B). However, the response was almost abolished
by the triple-receptor antagonism provided by the combination
FIG 4. Measurement of mannitol-induced release of histamine, CysLT, PGD2, PGE2, and 6-keto PGF1a. Me-
dia were collected in the absence (number of patients5 7, number of segments used5 7) or presence (num-
ber of patients 5 4; number of segments used 5 4) of indomethacin (Indo; 3 mmol/L) 20 minutes after
addition of mannitol. Data represent means 6 SEMs, *P < .05 and **P < .01.
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16.6% 6 1.6%; P < .05; Fig 2, A and B). Likewise, the mast
cell–stabilizing agent cromolyn inhibited the mannitol-
induced contraction (Emax, 22.7% 6 3.4%; P < .05; Fig 2, A
and B). In line with the first results, the initial small contraction
in the presence of mannitol was not inhibited by the triple antag-
onism or cromolyn (Fig 2, B). On the other hand, the unselective
COX inhibitor indomethacin augmented the contraction induced
by mannitol exposure (Emax, 71.6% 6 4.8%; P < .05; Fig 2, C
and D).
The histologically verified removal of the airway epithelium in
segments (Fig 3, A and B) did not affect the control response to
mannitol or the enhanced response by indomethacin (Emax,
67.1% 6 7.0%; Fig 3, C).Mannitol induces release of mast cell mediators
Tissue bath buffer was collected for analysis 20 minutes after
continuous exposure to mannitol to document the release of mast
cell mediators. In medium from mannitol-exposed segments,
marked increases in values of histamine (1570 6 258 vs
175.2 6 85.3 pg/mg, 9.0-fold; P < .05), CysLTs (50.0 6 12.8
vs 11.4 6 5.3 pg/mg, 4.4-fold; P < .05), PGD2 (14.6 6 2.7 vs
2.7 6 1.1 pg/mg, 5.4-fold; P < .05), PGE2 (125.9 6 32.9 vs
20.2 6 4.7 pg/mg, 6.2-fold; P < .05), and the hydrolysis product
of prostacyclin 6-keto PGF1a (33.86 7.5 vs 6.26 1.3 pg/mg, 5.5-
fold; P < .05) were found compared with values in control
segments.Mannitol exposure was performed in the presence of the
unselective COX inhibitor indomethacin (3 mmol/L) to further
investigate the involvement of prostanoids. Release of PGD2
(0 6 0 pg/mg), PGE2 (18.0 6 5.2 pg/mg), and 6-keto PGF1a
(4.1 6 1.5 pg/mg) was inhibited by indomethacin (P < .05),
whereas neither CysLTs nor histamine were affected (Fig 4).Evidence that endogenous PGE2 and PGI2 repress
mannitol-induced contractions
The possible involvement of COX products responsible for
increased contractility after treatment with indomethacin were
first pharmacologically characterized by using specific receptor
antagonists and agonists for PGE2. Pretreatment with the EP2 re-
ceptor antagonist PF-04418948 (1 mmol/L; Emax, 67.8%6 3.8%)
or the EP4 receptor antagonist ONO-AE3-208 (1 mmol/L; Emax,
65.6% 6 6.4%) caused an increase of the maximal contraction
to mannitol (P <.05). Consistent with the effects of the EP2 antag-
onist, treatment with the selective EP2 receptor agonist ONO-
AE1-259 abolished contraction after the mannitol washout period
(Fig 5, A).
Next, evidencewas obtained implicating that endogenous PGI2
also modulated the response to mannitol. Thus pretreatment with
the IP receptor antagonist CAY 10441 (1 mmol/L; Emax,
68.6%6 4.6%) induced a similar increase inmaximal contraction
tomannitol (P <.05) as seenwith the EP2 and EP4 antagonists (Fig
5, B and C). The relaxant property of the IP receptor was
confirmed in bronchial segments precontracted with carbachol
FIG 5. Responses of human small bronchi. A and B, Time-response contractions after 10 minutes of
increased osmolarity by mannitol in the presence or absence of PF-04418948 (1 mmol/L), ONO-AE3-208
(1 mmol/L), or ONO-AE1-259 (1 mmol/L; Fig 5, A) or CAY 10441 (1 mmol/L; Fig 5, B). C, Emax displays contrac-
tion in relation to maximal contractility during (black bar) or after (white bar) normalized osmolarity (num-
ber of patients 5 5, number of segments used 5 5). *P < .05 and **P < .01. D, Cumulative addition of
salbutamol or cicaprost in the presence or absence of the selective IP receptor antagonist CAY 10441
(1 mmol/L) on segments precontracted with carbachol (1 mmol/L) in the presence of the EP2 receptor antag-
onist PF-04418948 (1 mmol/L) and EP4 receptor antagonist ONO-AE3-208 (1 mmol/L; number of patients 5 5,
number of segments used5 5-8). Data represent means6 SEMs, and in Fig 5, B, the control (dotted line) is
reproduced from Fig 5, A.
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04418948 (1 mmol/L) and the EP4 receptor antagonist ONO-
AE3-208 (1 mmol/L). In this setting, in bronchi unexposed to
mannitol, the selective IP agonist cicaprost caused a
concentration-dependent relaxation (pEC50, 7.86 0.1; minimum
effect [Emin], 94.3% 6 1.6%). Pretreatment with the selective IP
receptor antagonist CAY10441 (1mmol/L) produced both a right-
ward shift of the concentration-response relationship, as well as
reduced relaxation to cicaprost (pEC50, 6.1 6 0.1; Emin,
73.3%6 6.1%; P <.05). In comparison, the clinically used b2 re-
ceptor agonist salbutamol was both less potent and efficacious
(pEC50, 7.36 0.1; Emin, 72.0%6 6.6%; P < .05) in the same tis-
sue (Fig 5, D).Bronchial responses in relation to donor
characteristics
Table I summarizes characteristics of the subjects from whom
small bronchi were obtained. There were no sex differences be-
tween clinical baseline data nor did the response of segments to
mannitol relate to sex, age, body mass index, allergy, or the indi-
cation for surgery (data not shown). None of the preparations
from subjects with doctor-diagnosed asthma (6/48) or spirometry
indices suggesting chronic obstructive pulmonary disease (5/48)responded qualitatively or quantitatively differently from other
preparations.DISCUSSION
This study introduces a new experimental protocol in explanted
human small airways in which brief exposure to hyperosmolar
mannitol triggers mast cell–dependent contractions. The support-
ing evidence included both characteristic pharmacology and
actual measurement of mast cell mediators in the tissue bath.
Furthermore, applying both global inhibition of COX biosyn-
thesis with indomethacin and specific pharmacologic antagonism
of EP2, EP4, and IP receptors, the investigation indicates that
endogenous PGE2 and PGI2 exert negative feedback functions
that dampen the consequences of mast cell activation.
First, the conundrum that mannitol is an effective stimulus for
bronchoconstriction when inhaled in asthmatic patients but not in
the previously published work on isolated airways was resolved.
It was confirmed that persistent hyperosmolar stimulation causes
a contracture that cannot be altered by mast cell inhibitors or
relaxant agents.13 The preparation appeared paralyzed and did not
react to supermaximal concentrations of histamine. Previous
work with bovine tracheal strips suggests that this unresponsive-
ness can be explained by a block of the excitation-contraction
J ALLERGY CLIN IMMUNOL
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the solution is that brief exposure of the isolated bronchi is enough
to cause a strong release of mediators without arresting the
smooth muscle in a contractile state. Furthermore, the concentra-
tion found to have the strongest effect, 850 mOsm, can simulate
the conditions for EIB because it has been estimated that the os-
molarity of the airway liquid surface is around 900 mOsm after
exercise.17
Second, it was demonstrated that the main contraction after the
transient mannitol exposure was due to release of mast cell
mediators based on 3 lines of evidence. First, the contraction was
associated with release of histamine, CysLTs (LTC4, LTD4 and
LTE4), and PGD2 into the tissue bath. Second, combined pharma-
cologic antagonism of the H1 receptors for histamine, the TP re-
ceptor for PGD2, and the CysLT1 receptor for the CysLTs
completely abolished the response. Finally, the mast cell stabi-
lizer cromoglycate attenuated the reaction. The same set of sup-
port has been shown for IgE-dependent contractions of this
human small airway preparation.12 Thus the main contraction
induced by mannitol was partly inhibited by montelukast or cro-
molyn, findings that are similar to the effects of interventions with
these mechanisms in patients with EIB.18-21
Although the level of histamine was the greatest of the
measured mediators after mannitol stimulation (31-fold greater
than CysLTs), the contraction was not significantly reduced by the
H1 receptor antagonist alone. This agrees with data for single
antagonism after anti-IgE challenge in human bronchi22 or EIB
in adult asthmatic patients23 showing that antagonism of CysLTs
alone was more efficacious than antihistamines, which is in line
with the consistent findings that the CysLTs are about 1000-fold
more potent than histamine in human bronchi and, in addition,
cause more long-lived contractions.24,25 Likewise, TP antago-
nism of PGD2 alone did not significantly inhibit the peak
response, although the value was numerically smaller.
The phenomenon that more powerful contractions of main
agonists (CysLTs in this case) can mask responses to comediators
that are less potent has been described for mast cell–dependent
contractions in other models.26 Thus the complex activation of
several contractile receptors during hyperosmolar exposure in
bronchial segments might be similar in patients with EIB and sup-
port the need of treatment with a combination of receptor antag-
onists. The approach to inhibit all 3 main classes of mast cell
mediators (CysLTs, histamine, and PGD2) was demonstrated to
be effective here but has not yet been tested in asthmatic patients
either for EIB or allergen-induced bronchoconstriction.
Third, there was also release of PGE2 and the metabolite of
PGI2, 6-keto PGF1a, after mannitol challenge. This is another
similarity with the in vivo situation. Metabolites of these 2
prostanoids have been recovered in urine from asthmatic
patients after eucapnic voluntary hyperpnea with dry air to mimic
EIB.11 Although not proved in this first study, it is presumed that
these 2 bronchoprotective prostanoids are released from other
sources than mast cells, such as epithelial cells, fibroblasts,
macrophages, and endothelial cells. We base this assumption on
data we recently published on the kinetics of lipid mediator
release after challenge with anti-IgE in human bronchi.27
Whereas release PGD2 and LTC4 peaked at 15 minutes after
challenge, PGE2 and 6-keto PGF1a showed slower increments
that increased with time.
Furthermore, in line with in vivo studies28 and work using anti-
IgE stimulation of the isolated small bronchi,12 PGE2 was clearlyimplicated as one component of the indomethacin-enhanced
response to mannitol. The study showed that both the EP2 and
EP4 receptors were involved and had the same overall effects
on the reaction. Based on the previous study of mast cell–
dependent contractions in this model,12 it is suggested that the
EP2 effect involves inhibition of mast cell mediator release,
29,30
whereas the EP4 response is due to smooth muscle relaxation.
12,31
Again, it remains for futurework to define the mode of action also
in this model. However, the contraction was almost completely
abolished when the segments were pretreated with the EP2 recep-
tor agonist. This inhibitory effect replicates the effect of inhaled
PGE2 before exposure to EIB.
5
Concerning PGI2, itwas somewhat surprising that antagonismof
the IP receptor had such a profound enhancing effect on the
mannitol reaction. For the first time, these data demonstrate that
activation of the IP receptor by an endogenous agonist has a protec-
tive role on the hyperosmolar-induced contraction. Therefore we
further characterized the influence of IP receptor activation on the
small airways. The previously described relaxant properties of
PGI2
32 and its analogues33 were confirmed by relaxation induced
by the IP receptor agonist cicaprost, which was blocked by the
antagonist CAY10441. Compared with previous studies,33 cicap-
rost had a 10-fold greater potency and amarkedly stronger relaxant
effect in the present study. This might be due to the small airways
used in the current study and more central airways in previous
studies. This study has not addressed whether PGI2 in addition to
bronchorelaxation also canmodulate release ofmast cellmediators.
Absence of the epithelium did not modify the contraction
response to mannitol challenge in this study either at baseline or
after treatment with indomethacin. This was a surprise because
data generally suggest that the epithelium is the major source of
PGE2.
34 Because the study found that antagonism of 3 different
receptors (EP2, EP4, and IP) provided similar effects as the
COX inhibitor indomethacin, it appears that there are parallel
pathways for endogenous protection against hyperosmolar activa-
tion of mast cells. However, the comparison with indomethacin is
not straightforward because the intervention also removes con-
tractile prostanoids, such as PGD2, thromboxane A2, and
PGF2a. Therefore the relative role of the inferred prostanoids in
the phenomenon of refractoriness to repeated exercisewill require
new studies taking into account the amounts released, their ki-
netics, their interactions, and responses to specific interventions
with distal enzymes catalyzing the formation of individual pri-
mary prostanoids.
Induction of contractions to mannitol in bronchi that were
mostly from nonasthmatic donorsmight seem contradictory to the
clinical use of mannitol for diagnosis of asthma and airway
hyperresponsiveness. However, we have previously documented
that nonasthmatic subjects in vivo release mast cell mediators
when inhaling mannitol, although they do not react with broncho-
constriction.9 Responsiveness to hyperosmolar challenge also oc-
curs in nonprimed isolated mast cells,13,14 but it remains to be
explained why the nonasthmatic isolated bronchi contracted in
response to released mediators. One possibility is that cutting
the bronchi into segments and placing them in tissue baths disrup-
ted the structural barriers and created improved opportunities for
the released mediators to reach smooth muscle cells. Thus exper-
imental procedures might mimic typical factors associated with
the asthmatic phenotype, such as diminished integrity of the
airway epithelium,35 infiltration of mast cells into the smooth
muscle compartment,36 and increased airway responsiveness.37
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mannitol challenge of isolated human bronchi, the results
mimicked airway constriction, mediator release, and pharmaco-
logic responses when EIB is triggered in asthmatic patients
in vivo. We found that hyperosmolar exposure caused contrac-
tions explained by the release of contractile mediators from
mast cells in the tissue but also the release of prostanoids repres-
sing the contraction. In addition to the expected inhibitory effect
of PGE2, for the first time, this study found evidence that endog-
enous prostacyclin should be considered as a potent bronchopro-
tective mediator. Because potent IP agonists are used to treat
pulmonary hypertension, it would seem possible in the near future
to translate our findings into proof-of-concept studies of whether
the IP receptor is a suitable new target for treatment of asthma in
general and EIB in particular.
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Key messages
d A new protocol for ex vivo challenge of explanted human
small airways with mannitol has been developed.
d The challenge triggers a mast cell–dependent contraction
mimicking EIB in vivo.
d PGE2 and prostacyclin are released as well, and they act
as bronchoprotective modulators.REFERENCES
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